Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis

Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

(2018) Kohei Kaku et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment

(2018) Lene Jensen et al.   DIABETES OBESITY & METABOLISM

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

(2018) Helena W Rodbard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

(2017) Bo Ahrén et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

(2017) Christopher Sorli et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis

(2016) Rune V. Overgaard et al.   CLINICAL PHARMACOKINETICS

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

(2016) Michael Nauck et al.   DIABETES CARE

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

(2015) Lisbeth V. Jacobsen et al.   CLINICAL PHARMACOKINETICS

Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials

(2015) Jeanne S. Geiser et al.   CLINICAL PHARMACOKINETICS

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

(2015) Christoph Kapitza et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

(2015) Jesper Lau et al.   JOURNAL OF MEDICINAL CHEMISTRY

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Cardiovascular Disease in Type 2 Diabetes From Population to Man to Mechanisms: The Kelly West Award Lecture 2008

(2010) M. Laakso   DIABETES CARE

Diabetes and Cancer: A consensus report

(2010) E. Giovannucci et al.   DIABETES CARE

Relationship Between Obesity and Diabetes in a US Adult Population: Findings from the National Health and Nutrition Examination Survey, 1999–2006

(2010) Ninh T. Nguyen et al.   OBESITY SURGERY

Confirmatory analysis for phase III population pharmacokinetics

(2009) Chuanpu Hu et al.   PHARMACEUTICAL STATISTICS

Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus

(2008) Bethany B. Barone   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The incretin system and its role in type 2 diabetes mellitus

(2008) J HOLST et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY